Prostate Cancer - Results from #240

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. September 18, 2024

Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors September 17, 2024

Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes September 17, 2024

Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study September 17, 2024

Integrative identification of non-coding regulatory regions driving metastatic prostate cancer. September 17, 2024

Risk of Anxiety Disorders in Men With Prostate Cancer: A National Cohort Study. September 17, 2024

Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment. September 17, 2024

Ejaculatory function after radiotherapy for prostate cancer: a systematic review and meta-analysis. September 17, 2024

Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database. September 17, 2024

Intra-prostatic recurrences after radiotherapy with focal boost: Location and dose mapping in the FLAME trial. September 17, 2024

Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study. September 17, 2024

Extracellular Vesicles heterogeneity through the lens of multiomics. September 17, 2024

Prostate cancer disparities in clinical and survival patterns among Black and Latino patients considering nativity: findings from the California Cancer Registry. September 17, 2024

Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment. September 17, 2024

MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer. September 17, 2024

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer. September 17, 2024

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study September 16, 2024

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. September 16, 2024

Proteomic landscape profiling of primary prostate cancer reveals a 16-protein panel for prognosis prediction. September 16, 2024

'Just because I have prostate cancer doesn't mean that I can't do things' - men's experiences of the acceptability of an exercise intervention for prostate cancer during treatment. September 16, 2024

Page 13 of 1436